FLT3 and acute myeloid leukemia: The incorporation of venetoclax and FLT3 inhibitors in triplet therapy regimens, often combined with low-intensity agents, has shown encouraging response rates and MRD negativity in both newly diagnosed and relapsed/refractory AML cases.